DCM
NVCR icon

Dialectic Capital Management’s NovoCure NVCR Stock Holding History

Dialectic Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,000
Closed -$145K – 118
2016
Q1 		$145K Buy
+10,000
New +$143K 0.07% 93

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dialectic Capital Management's NVCR Position: Q2 2016 in Review

Dialectic Capital Management sold out of NovoCure (NVCR) in Q2 2016, closing a stake of 10,000 shares — an estimated $145K sold.

Dialectic Capital Management first reported a position in NVCR in Q1 2016 and held it in 1 quarter. The position peaked at $145K in Q1 2016. 66 funds tracked by Wall St. Rank hold NVCR as of Q2 2016.

  • Dialectic Capital Management reported no remaining NovoCure position as of Q2 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 10,000 NovoCure shares in Q2 2016, an estimated $145K.
  • Dialectic Capital Management first reported a position in NovoCure in Q1 2016 and held it in 1 quarter.
  • Dialectic Capital Management's NovoCure position peaked at $145K in Q1 2016.
  • 66 funds tracked by Wall St. Rank held NovoCure as of Q2 2016.

Based on Dialectic Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.